EGREGIOUS ERROR OR ADMIRABLE ADVANCE: THE
MEMORANDUM OF UNDERSTANDING THAT ENABLES FEDERALLY
FUNDED BASIC HUMAN EMBRYONIC STEM CELL RESEARCH
Nothing contained herein shall be considered to be the grant of a commercial
license or right under the Wisconsin Patent Rights or to Wisconsin Materials.
Furthermore, nothing contained herein shall be construed to be a waiver of
WiCell’s patent rights under the Wisconsin Patent Rights or WiCell’s property
rights in Wisconsin Materials.1

Introduction
The federal government designated the National Institutes of Health (NIH) to negotiate an
agreement to allow researchers access to the human embryonic stem cell lines specified under federal
research guidelines. The stem cell lines available in the United States are controlled by the WiCell
Research Institute and, in part, Geron Corporation. On September 5, 2001, NIH and WiCell signed a
Memorandum of Understanding (MOU) that granted federally funded researchers access to WiCell’s stem
cell lines for basic research purposes only and waived WiCell’s reach-through rights on the resulting
discoveries. The MOU does have the clear benefit of enabling important basic research yielding many
potential medical benefits. The problem with the MOU is that after basic research, WiCell and Geron can
potentially block all or selected commercial and therapeutic development and usages involving WiCell
and Geron intellectual property. In essence, the federal government is funding the expanded basic
research of two private companies that already have a legal monopoly on a broad set of stem cell products
and methods under pre-existing patent rights, while providing no safeguards on the licensing activities of
the patent holders.

What Is Human Embryonic Stem Cell Research? 2
Human embryonic pluripotent stem cells (HEPSCs) were first isolated in 1998 by James
Thomson at the University of Wisconsin at Madison. As standard in vitro fertilization creates many
excess human embryos, many participants of the treatment have decided to donate their excess embryos
for research purposes. Embryonic stem cells are created from the inner cell mass of a week-old human
embryo created in the course of the infertility treatments. With proper culture, the embryonic stem cells
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can grow and divide indefinitely, with the potential to develop into almost all types of body tissues. A
stem cell line is a cell population that reproduces from the original embryonic stem cell that shares its
genetic characteristics.

After replication in culture, cells from the cell line can be distributed to

researchers.

The Legal Background for Human Embryonic Stem Cell Research
When Thomson established the first HEPSC line in 1998, Geron Corporation of Menlo Park,
California, sponsored Thomson’s research, as no government funding was available. Thomson was
granted three patents, which are held by the Wisconsin Alumni Research Foundation (WARF). United
States Patent 5,843,780 issued on December 1, 1998 and claims primate embryonic stem cells, United
States Patent 6,200,806 issued on March 13, 2001 and claims a purified preparation of HEPSCs, and
United States Patent 6,280,718 issued on August 28, 2001 and claims the method of hematopoietic
differentiation of HEPSCs.

WARF then granted an exclusive commercial license to Geron to

commercialize products based on a limited six cell types of medical importance: liver, muscle, nerve,
pancreas, blood, and bone.3 WARF has recently sued to restrain Geron from extending its commercial
rights in WARF’s cell lines to an additional 12 derivative cell types.4 In addition to Geron’s rights under
the WARF patents, Geron also has patent rights to future stem cell developments as it filed additional
patents on techniques of growing stem cells and on controlling differentiation into a specific cell type.5
WARF and other cell providers have publicly stated that they are interested in making their cells available
for use in federally funded research. 6 The Wisconsin stem cell lines are currently available from WiCell
Research Institute, a WARF subsidiary, to any research group that signs a Materials Transfer Agreement
to use them for only basic research.
Before August 2001, the U.S. House of Representatives had already passed a bill banning cloning
of human cells for research purposes. On August 9, 2001, President Bush officially announced his
support for limited federal funding for human embryonic stem cell research. The conditions to gain
federal funding for a quality stem cell line in existence on August 9, 2001 are that the original embryonic
stem cell: (1) was gained through the informed consent of the parents; (2) the cells must have been
created from excess embryos produced in an in-vitro fertilization laboratory; (3) the cells must not have
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been produced for the purposes of research; and (4) donors must not have been given a financial
incentive.7

The stem cell line derived from the original embryonic stem cell must be viable, show

characteristic stem cell morphology, have the ability to be maintained frozen and in culture, and have
undergone at least several population doublings.8
Sixty-four embryonic stem cell lines met the presidential criteria. The decision restricts federally
funded scientists from obtaining human embryonic stem cells from lines other than the 64 existing cell
lines that met the presidential criteria. The 64 lines were reported from ten different laboratories in the
United States, Australia, India, Israel, and Sweden. 9 The majority of lines were even reported to express
all of the markers known to be associated with human embryonic stem cells, including stage specific
embryonic antigens, the enzyme alkaline phosphatase, and tumor rejection antigen 1. 10
To implement the President’s decision, the NIH is currently attempting to create a Human
Embryonic Stem Cell Registry of the sixty-four existing stem cell lines around the world that meet the
eligibility criteria. While basic contact information and data are sought at present, the NIH hopes to
expand the registry to include derivation details, the number of passages, culture conditions, and growth
characteristics, a description of efforts to characterize the cells, relevant publications, DNA fingerprinting
data, and quality assurance data.11 The Food and Drug Administration also stands ready to work with the
scientific community as stem cell research nears the stage of human clinical trials.
Regardless of the federal view regarding embryonic stem cell research, the regulatory problem
may remain with the states. Numerous states already govern research on embryos and fetuses and
approximately nine states ban human embryo experimentation. 12 This means that even approved stem
cell lines or the commercial and therapeutic products resulting from those stem cell lines could be barred
from being sold within these states.

The Memorandum Of Understanding (MOU)
To solve some of the technology transfer issues involved in gaining access to HEPSCs, the NIH
signed an agreement on September 5, 2001 with the WiCell Research Institute, Inc., of Madison,
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Wisconsin. 13 WiCell is the group that holds the patents on human embryonic stem cells and the MOU
with the NIH makes WiCell’s existing five human embryonic stem cell lines more readily available to
federally funded researchers.14 Under the agreement with WiCell, scientists at the NIH have free rein to
do basic embryonic stem cell research, though the creation of whole embryos or the use of the cell
samples for therapeutic or diagnostic purposes is forbidden. 15 The agreement also enables researchers to
be unencumbered by intellectual property disputes as WiCell is forgoing any claim of patent rights to new
discoveries that researchers discover during basic research. WiCell retains commercial rights to its
materials and will receive a fee to cover handling and distribution expenses in supplying the cell lines. In
addition, WiCell agrees within the MOU to allow federally funded non-profit institutions access to the
stem cell lines upon the negotiation of similar agreements.

Disadvantages Of The Memorandum Of Understanding
The public should be concerned that their tax dollars are effectively funding the basic research of
two private companies without limitation to the potential future royalties of the companies. Of course, the
government also retains a royalty-free license to use inventions that result from government funded
research, regardless of whether the research was done in an NIH laboratory or a private institution. While
such a practice may be common in other scientific industries, military equipment for example, the
monopoly on HEPSCs has a much broader potential for future inventions and technologies in many
different scientific fields and the results are predicted to have fewer latency problems. The estimated 8 to
12 years until commercial and therapeutic products or uses are realized may enable WiCell to enjoy more
of the patent term protection of their monopoly than is usual.
Having legally and fairly granted a monopoly to WiCell through the patent system, the
government’s MOU basically gave the patentee a blank check by not negotiating potential licensing
practices, fees, or royalties upfront. In addition, the President’s decision has limited the development of
additional embryonic stem cell lines, thereby limiting the threats to Wisconsin’s or Geron’s domination of
the field within the United States. Since WiCell lawfully acquired the patent, WiCell cannot be held
liable under the Sherman Act § 2, 15 U.S.C.S. §2, for maintaining the monopoly power they lawfully
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acquired by refusing to license the patent to others.16 As long as WiCell and Geron do not try to extend
the monopoly to unpatented material, they are basically safe from antitrust liability. 17
Under the MOU, WiCell has signed away any reach-through rights to discoveries or inventions
resulting from basic research. Basically, any researcher who makes a patentable discovery through basic
research with WiCell’s embryonic stem cell lines will own the patent.18 But if the researcher wishes to
commercialize any discovery made on the basis of WARF’s patent, they must negotiate a license with
WARF. At present, WiCell currently has 30 Material Transfer Agreement’s (MTAs) executed for the
human embryonic stem cells and approximately another 100 MTAs in various stages of negotiation with
various academic and nonprofit research institutions.19

In addition, anyone seeking to develop

commercial applications of stem cells to the six cell types exclusively licensed to Geron will also have to
negotiate with Geron for a sublicense.20 If an agreement cannot be reached, the patent holder must go
directly to WARF, as Geron has no legal right to enforce WARF’s patent. In an agreement similar to the
MOU between NIH and WiCell, Geron has agreed to allow academic scientists to convert the stem cells
into the derivative cell types covered by its agreement with WiCell, but refuses to allow
commercialization of the results at this time. Geron has stated that it does not want to impede others from
research into the basic biology of stem cells or therapeutic applications but will demand royalties from
any commercial products or therapies that are developed. 21 Unlike the MOU between NIH and WiCell,
Geron has assured WARF and WiCell that it will sublicense on reasonable commercial terms.22 As a
result, Geron will most likely maximize the number of companies developing commercial products in
order to maximize the amount of potential royalties.
No concern is evident within the MOU for the possibility that the patent holder may choose to
exercise its rights through licensing or other contractual agreements in a manner inconsistent with the
advancement of therapeutic and commercial applications. After allowing the NIH and private federally
funded scientists to finish the basic research on WiCell’s HEPSC lines, WiCell could potentially block all
or selected commercial and therapeutic development and usage through restrictive licensing. At present,
there are no written limitations on to whom and on what terms licensing by WiCell and Geron will be
16
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granted. The Government has granted a monopoly, funded it, and apparently failed to consider balances
or limitations. It appears that NIH wanted its researchers to have sole access to the HEPSC lines for basic
research and a chance to protect the rights of the rest of the HEPSC industry may have been missed. This
apparent lack of forethought not only limits competition, but also slows therapeutic and commercial
research of stem cells. The only alternative for competitors is to attempt to negotiate with WiCell and
Geron or to design around the patents, for example by employing human germ-cell lines derived from
aborted fetuses and adult stem cells.
NIH should have negotiated a royalty agreement and/or inserted a fair, reasonable, and
nondiscriminatory licensing clause within the MOU to limit, in a reasonable manner, WiCell’s monopoly
in return for providing WiCell with such a major boost in basic research likely to use WiCell intellectual
property. While such clauses may necessitate litigation at a later date, the clauses would effectively limit
injunctions against the infringing parties that could stifle competition and retard product development. A
deficiency of this approach is that such clauses might only protect the larger and more competitive
pharmaceutical companies, but there would be some protection for the competitive market. Although the
Government could not and should not force WiCell to forfeit its intellectual property rights, the
publicizing of WiCell’s unwillingness to allow the reasonable royalty or licensing clauses within the
MOU would have essentially forced the company to capitulate. Difficulties with these clauses would be
in drafting specific conditions as stem cell research is still in its infancy and neither the breadth of
potential products nor their value is clear.
The Government also missed the opportunity to grant and define a strong research exemption to
give third parties access to stem cell products and research tools for research purposes without having to
obtain permission from the patent holder or to require WiCell and Geron to agree to compulsory licensing
under limited and clearly defined circumstances within the MOU. Scientists usually have a research-use
exemption that provides protection from patent infringement when the patented invention is used for
research purposes only. 23 Then, if a discovery during basic research leads to a commercially valuable
invention, WiCell could still exclude the discoverer from making, using, and selling the invention. 24 This
research exemption would just make the access to WiCell’s stem cell lines a bit less complicated.
Under the MOU, WiCell allows third-party stem cell lines to be used for basic research with
immunity from infringement injunctions but with the restriction that the third party may not directly or
indirectly retain rights to their materials.25 In addition, laboratories that utilize both WiCell and third-
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party lines may only use the HEPSC lines for teaching or non-commercial research purposes.26 This
excludes sponsored research where the sponsor receives a right to the results of the sponsored research.
This requirement of the MOU basically limits labs to federal funding and WiCell lines. If the labs want to
use third party lines with private funding, they run the risk of an infringement suit by WiCell. If they want
to use WiCell lines, they cannot have private funding and are limited to federal funding resources.
Basically, WiCell has a win-win situation to continue its U.S. domination of the stem cell research field.
The NIH could have also negotiated a broader covenant not to sue from WiCell. This is
important, as international laboratories are afraid to make or sell their stem cell lines in the United States
for fear of an infringement suit from WiCell. These companies must obtain a license from WARF if the
cells match the WARF’s patent description. While WiCell cannot sue international laboratories that
‘give’ portions of their cell lines to federally funded American researchers, WiCell can sue the American
researchers who take the international cell lines for infringement under WiCell’s patent monopoly.
WiCell can obtain an injunction against anyone who makes, sells, or uses an infringing stem cell line.
This patent monopoly gains WiCell almost an exclusive hold on all federally funded embryonic stem cell
research within the legal boundaries of the United States. In the alternative, WiCell can allow the
government to fund the research on the international cell lines, get the information, and then sue for
infringement before or when a commercial or therapeutic use is developed. By reserving the right to sue
until after the basic research is accomplished, WiCell could potentially force excessive license fees upon
the inventive party.
Still, the cell lines within international borders are not limited by President Bush’s decision or
WARF’s patent monopoly within the United States. Because of this and as a result of the adoption of
more liberal policies regarding the use of human embryonic stem cells in other countries, the United
States is losing talented researchers who want to continue their research in a more receptive
environment.27 While WARF and Geron have both filed for numerous international patents, all of the
patent filing requests are still within the application phase at present and pose no immediate danger of
infringement suits.28
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Benefits Of The Memorandum Of Understanding
The most important benefit of the MOU is that it enables researchers to gain access to WiCell’s
stem cell lines for basic research. Despite the block on therapeutic and commercial research by the MOU,
the estimated gain of information from the federally funded basic research retains an enormous potential.
From the basic research, scientists hope to create a fundamental base of knowledge about how the stem
cells function and how to manipulate them.

Examples include determining the best conditions for

growing the cells, directing the differentiation of the stem cells into specialized cells, and learning about
key genes that control proliferation of the stem cells in an undifferentiated state.
The second most important benefit of the MOU is that it enables researchers to gain access to
stem cell lines that qualify for federal funding under the President’s criteria. Government assistance in the
form of federal funding is necessary in order to ensure equal access to the qualified stem cell lines, to
promote investment in this promising line of research, to encourage sound public policy, and to foster
public confidence in the conduct of such research. 29 In addition to being the most efficient way to further
basic embryonic stem cell research, federal funding is the only realistic source for the large and sustained
infusion of funds that is necessary for the research. President Bush’s federal funding plan, now enabled
by the MOU, may also provide motivation for the private sector to get involved and transform the basic
research into disease therapies.30
A third benefit of the MOU is that it will expedite the research on stem cells. The MOU enables
multiple parties to pursue simultaneously this critical research, and thereby increases the chances for
significant discoveries over a shorter period of time. The MOU also provides a comprehensive ethical
oversight to the stem cell research. Private organizations and overseas researchers will still have stem cell
research, but without the comprehensive ethical oversight provided by U.S. human subjects regulations.31
The potential benefits to the public may be greater than the risk of financing a private and legal
monopoly. Right now, the NIH has satisfied its goal as a basic research institution to gain its scientists
access to the research tools. Only the future will tell us whether the lack of limitations on the patent
holder was worth the gain.
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Conclusion
Many scientists believe that human embryonic stem cell research holds incredible promise over
time because of the capacity of embryonic stem cells to develop into any tissue in the human body. The
NIH’s MOU with WiCell has enabled federally funded researchers to gain access to WiCell’s HEPSC
lines for basic research. While there seems to be an egregious lack of foresight in limiting WiCell’s legal
monopoly over HEPSC development in return for the federal funding boost to basic research involving
WiCell’s patents, the basic research that has been expedited may lead to creating therapies for diseases
like Parkinson’s and Alzheimer’s, or even to evaluate the safety and efficacy of new medicines from an
increased understanding of basic biology.
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